Cargando…
Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses
Mucopolysaccharidoses (MPSs) are a group of lysosomal storage disorders associated with impaired glycosaminoglycans (GAGs) catabolism. In MPS I, II, III, and VII, heparan sulfate (HS) cannot be degraded because of the lack of sufficient activity of the respective enzymes, and its accumulation in the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151490/ https://www.ncbi.nlm.nih.gov/pubmed/32183018 http://dx.doi.org/10.3390/diagnostics10030155 |
_version_ | 1783521262263336960 |
---|---|
author | Baydakova, Galina Ilyushkina, Alex Gaffke, Lidia Pierzynowska, Karolina Bychkov, Igor Ługowska, Agnieszka Wegrzyn, Grzegorz Tylki-Szymanska, Anna Zakharova, Ekaterina |
author_facet | Baydakova, Galina Ilyushkina, Alex Gaffke, Lidia Pierzynowska, Karolina Bychkov, Igor Ługowska, Agnieszka Wegrzyn, Grzegorz Tylki-Szymanska, Anna Zakharova, Ekaterina |
author_sort | Baydakova, Galina |
collection | PubMed |
description | Mucopolysaccharidoses (MPSs) are a group of lysosomal storage disorders associated with impaired glycosaminoglycans (GAGs) catabolism. In MPS I, II, III, and VII, heparan sulfate (HS) cannot be degraded because of the lack of sufficient activity of the respective enzymes, and its accumulation in the brain causes neurological symptoms. Globotriaosylsphingosine (LysoGb3), the deacylated form of globotriaosylceramide (Gb3), is described as a highly sensitive biomarker for another lysosomal storage disease—Fabry disease. The connection between MPSs and LysoGb3 has not yet been established. This study included 36—MPS I, 15—MPS II, 25—MPS III, 26—MPS IV, and 14—MPS VI patients who were diagnosed by biochemical and molecular methods and a control group of 250 males and 250 females. The concentration of lysosphingolipids (LysoSLs) was measured in dried blood spots by high pressure liquid chromatography—tandem mass spectrometry. We have demonstrated that LysoGb3 concentration was significantly elevated (p < 0.0001) in untreated MPS I (3.07 + 1.55 ng/mL), MPS II (5.24 + 2.13 ng/mL), and MPS III (6.82 + 3.69 ng/mL) patients, compared to the control group (0.87 + 0.55 ng/mL). LysoGb3 level was normal in MPS VI and MPS IVA (1.26 + 0.39 and 0.99 + 0.38 ng/mL, respectively). Activity of α-galactosidase A (α-Gal A), an enzyme deficient in Fabry disease, was not, however, inhibited by heparan sulfate in vitro, indicating that an increase of LysoGb3 level in MPS I, MPS II, and MPS III is an indirect effect of stored MPSs rather than a direct result of impairment of degradation of this compound by HS. Our findings indicate some association of elevated LysoGb3 concentration with the neuronopathic forms of MPSs. The pathological mechanism of which is still to be studied. |
format | Online Article Text |
id | pubmed-7151490 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71514902020-04-20 Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses Baydakova, Galina Ilyushkina, Alex Gaffke, Lidia Pierzynowska, Karolina Bychkov, Igor Ługowska, Agnieszka Wegrzyn, Grzegorz Tylki-Szymanska, Anna Zakharova, Ekaterina Diagnostics (Basel) Article Mucopolysaccharidoses (MPSs) are a group of lysosomal storage disorders associated with impaired glycosaminoglycans (GAGs) catabolism. In MPS I, II, III, and VII, heparan sulfate (HS) cannot be degraded because of the lack of sufficient activity of the respective enzymes, and its accumulation in the brain causes neurological symptoms. Globotriaosylsphingosine (LysoGb3), the deacylated form of globotriaosylceramide (Gb3), is described as a highly sensitive biomarker for another lysosomal storage disease—Fabry disease. The connection between MPSs and LysoGb3 has not yet been established. This study included 36—MPS I, 15—MPS II, 25—MPS III, 26—MPS IV, and 14—MPS VI patients who were diagnosed by biochemical and molecular methods and a control group of 250 males and 250 females. The concentration of lysosphingolipids (LysoSLs) was measured in dried blood spots by high pressure liquid chromatography—tandem mass spectrometry. We have demonstrated that LysoGb3 concentration was significantly elevated (p < 0.0001) in untreated MPS I (3.07 + 1.55 ng/mL), MPS II (5.24 + 2.13 ng/mL), and MPS III (6.82 + 3.69 ng/mL) patients, compared to the control group (0.87 + 0.55 ng/mL). LysoGb3 level was normal in MPS VI and MPS IVA (1.26 + 0.39 and 0.99 + 0.38 ng/mL, respectively). Activity of α-galactosidase A (α-Gal A), an enzyme deficient in Fabry disease, was not, however, inhibited by heparan sulfate in vitro, indicating that an increase of LysoGb3 level in MPS I, MPS II, and MPS III is an indirect effect of stored MPSs rather than a direct result of impairment of degradation of this compound by HS. Our findings indicate some association of elevated LysoGb3 concentration with the neuronopathic forms of MPSs. The pathological mechanism of which is still to be studied. MDPI 2020-03-13 /pmc/articles/PMC7151490/ /pubmed/32183018 http://dx.doi.org/10.3390/diagnostics10030155 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Baydakova, Galina Ilyushkina, Alex Gaffke, Lidia Pierzynowska, Karolina Bychkov, Igor Ługowska, Agnieszka Wegrzyn, Grzegorz Tylki-Szymanska, Anna Zakharova, Ekaterina Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses |
title | Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses |
title_full | Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses |
title_fullStr | Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses |
title_full_unstemmed | Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses |
title_short | Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses |
title_sort | elevated lysogb3 concentration in the neuronopathic forms of mucopolysaccharidoses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151490/ https://www.ncbi.nlm.nih.gov/pubmed/32183018 http://dx.doi.org/10.3390/diagnostics10030155 |
work_keys_str_mv | AT baydakovagalina elevatedlysogb3concentrationintheneuronopathicformsofmucopolysaccharidoses AT ilyushkinaalex elevatedlysogb3concentrationintheneuronopathicformsofmucopolysaccharidoses AT gaffkelidia elevatedlysogb3concentrationintheneuronopathicformsofmucopolysaccharidoses AT pierzynowskakarolina elevatedlysogb3concentrationintheneuronopathicformsofmucopolysaccharidoses AT bychkovigor elevatedlysogb3concentrationintheneuronopathicformsofmucopolysaccharidoses AT ługowskaagnieszka elevatedlysogb3concentrationintheneuronopathicformsofmucopolysaccharidoses AT wegrzyngrzegorz elevatedlysogb3concentrationintheneuronopathicformsofmucopolysaccharidoses AT tylkiszymanskaanna elevatedlysogb3concentrationintheneuronopathicformsofmucopolysaccharidoses AT zakharovaekaterina elevatedlysogb3concentrationintheneuronopathicformsofmucopolysaccharidoses |